The user is using a hair regrowth protocol including dutasteride, topical and oral minoxidil, dermarolling, ketoconazole shampoo, and tretinoin, but is experiencing slow progress and seeks advice for faster regrowth. Suggestions include quitting smoking, adjusting the regimen, and considering additional treatments like topical finasteride or RU58841.
Creatine can cause increased hair loss in some people, particularly those with a predisposition to androgenic alopecia, but hair loss often stops after discontinuing its use. Some users experience no hair loss while using creatine.
A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
The user has been using topical finasteride and minoxidil since 2021 and is exploring other hair treatment companies like Xyon and Happy Head due to dissatisfaction with the current product's smell. They question the authenticity of consultations from these companies, suspecting they might be automated.
A 22-year-old male experienced hair thinning and found minoxidil ineffective, with blood tests showing deficiencies in zinc, vitamin B12, vitamin D3, and possible hypothyroidism. Another user suggested adding topical finasteride to the regimen, which helped them regrow hair effectively without side effects.
The conversation is about using tretinoin to enhance the effectiveness of minoxidil for hair loss. Tretinoin should be applied at night on dry skin, and it can be used daily, either before or after minoxidil, with a starting dose of 0.025%.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.